SEOUL, South Korea--(BUSINESS WIRE)--Jan 12, 2025--
FutureMain Co., Ltd., a leading provider of industrial AI-based predictive maintenance solutions, announced that it has successfully completed a proof of concept (PoC) with Saudi Aramco, Saudi Arabia’s state-owned oil company. Building on this achievement, the company has advanced its development efforts to complete a pilot project with upgraded functionalities by the first quarter of 2025. This marks a significant step in accelerating the entry of FutureMain’s flagship ExRBM solution into the Middle East. By leveraging localized technical support and robust networks, FutureMain aims to position the region as a strategic bridgehead for global expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109781597/en/
The ExRBM solution is an AI-driven predictive maintenance technology designed to monitor equipment conditions in real time, predict potential failures, and enable proactive responses. Notably, ExRBM excels in minimizing downtime and reducing maintenance costs through automated diagnostics that are tailored to specific types of equipment failures. This advanced technology is powered by FutureMain’s proprietary AI algorithms, which leverage 37 years of engineering data. Particularly well-suited to addressing the operational challenges of local industries, ExRBM offers a comprehensive solution to optimize facility management and enhance operational efficiency.
FutureMain has cemented its presence in the regional market by participating in prominent industry exhibitions such as GITEX and ADIPEC, where it has showcased its innovative solutions and technological expertise. Through these efforts, the company has signed MoUs with seven organizations, including Vestigos, Next IT, Colonel, Sensoteq, and Al Bahlaq. FutureMain is also in discussions with over 15 companies regarding local partnerships. Moreover, pilot projects for AI-powered facility diagnostic measurement systems are underway with entities such as UAE ADNOC Onshore, Offshore, and GAS.
Lee Sun-hwi, CEO of FutureMain, said, “We’re thrilled that the technological capabilities of ExRBM have been recognized once again in the Middle East through our successful collaboration with Aramco. We will remain committed to establishing FutureMain as a leader in AI-powered predictive maintenance technology across the Middle East by continuously expanding our global partnership network.”
FutureMain expands its Middle East footprint by completing a PoC with Saudi Aramco for its AI-powered ExRBM predictive maintenance solution (Image: FutureMain)
FutureMain showcases its AI-powered predictive maintenance solutions at prestigious exhibitions in Middle East (Image: FutureMain)
NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/
The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.
“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”
“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”
The deployment of Oracle Argus will enable QPS to:
As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.
###
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.
ABOUT ORACLE ARGUS
Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.
Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.
